Drug intelligence / Profile preview

SB-258741

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Intraperitoneal, Subcutaneous

Overview

SB-258741 is a potent and specific **5-HT7 receptor antagonist**. It has been studied for its potential therapeutic use in various conditions, including **sleep disorders**, **schizophrenia**, **depression**, **migraine**, **epilepsy**, **pain**, and **memory impairment**. It is known to behave as a **partial inverse agonist** at the 5-HT7 receptor. Developed by SmithKline Beecham Plc, it is currently in the preclinical stages.

Other names: R-(+)-1-(toluene-3-sulfonyl)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine

Targets

HTR7 (5-hydroxytryptamine receptor 7)

Beyond the preview

Go deeper on SB-258741.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB-258741.

Explore the full profile